Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy.

Historically, the tissue inhibitors of matrix metalloproteinases (TIMPs) were considered monochromatic in function. However, differential TIMP profiles more recently observed with left ventricular (LV) dysfunction and matrix remodeling suggest more diverse biological roles for individual TIMPs. This study tested the hypothesis that cardiac-specific overexpression (TIMP-4OE) or deletion (knockout; TIMP-4KO) would differentially affect LV function and structure following pressure overload (LVPO). LVPO (transverse aortic constriction) was induced in mice (3.5 ± 0.1 mo of age, equal sex distribution) with TIMP-4OE (n = 38), TIMP-4KO (n = 24), as well as age/strain-matched wild type (WT, n = 25), whereby indexes of LV remodeling and function such as LV mass and ejection fraction (LVEF) were determined at 28 days following LVPO. Following LVPO, both early (7 days) and late (28 days) survival was ~25% lower in the TIMP-4KO group (P < 0.05). While LVPO increased LV mass in all groups, the relative hypertrophic response was attenuated with TIMP-4OE. With LVPO, LVEF was similar between WT and TIMP-4KO (48 ± 2% and 45 ± 3%, respectively) but was higher with TIMP-4OE (57 ± 2%, P < 0.05). With LVPO, LV myocardial collagen expression (type I, III) increased by threefold in all groups (P < 0.05), but surprisingly this response was most robust in the TIMP-4KO group. These unique findings suggest that increased myocardial TIMP-4 in the context of a LVPO stimulus may actually provide protective effects with respect to survival, LV function, and extracellular matrix (ECM) remodeling. These findings challenge the canonical belief that increased levels of specific myocardial TIMPs, such as TIMP-4 in and of themselves, contribute to adverse ECM accumulation following a pathological stimulus, such as LVPO.

[1]  M. Zile,et al.  Myocardial fibroblast-matrix interactions and potential therapeutic targets. , 2014, Journal of molecular and cellular cardiology.

[2]  Michael E. Hall,et al.  Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling , 2014, Pflügers Archiv - European Journal of Physiology.

[3]  Michael E. Hall,et al.  Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. , 2013, Physiology.

[4]  Jeffrey A. Jones,et al.  Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. , 2012, American journal of physiology. Heart and circulatory physiology.

[5]  S. Goruppi,et al.  Decreased metalloprotease 9 induction, cardiac fibrosis, and higher autophagy after pressure overload in mice lacking the transcriptional regulator p8. , 2011, American journal of physiology. Cell physiology.

[6]  M. Zile,et al.  Plasma Biomarkers That Reflect Determinants of Matrix Composition Identify the Presence of Left Ventricular Hypertrophy and Diastolic Heart Failure , 2011, Circulation. Heart failure.

[7]  E. Benjamin,et al.  Relations of Biomarkers of Extracellular Matrix Remodeling to Incident Cardiovascular Events and Mortality , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[8]  C. Rochitte,et al.  Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. , 2010, Journal of the American College of Cardiology.

[9]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. , 2010, Seminars in cancer biology.

[10]  V. Regitz-Zagrosek,et al.  Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[11]  R. Khokha,et al.  Mice with Tissue Inhibitor of Metalloproteinases 4 (Timp4) Deletion Succumb to Induced Myocardial Infarction but Not to Cardiac Pressure Overload* , 2010, The Journal of Biological Chemistry.

[12]  F. Spinale,et al.  Cardiac-Restricted Overexpression of Membrane Type-1 Matrix Metalloproteinase in Mice: Effects on Myocardial Remodeling With Aging , 2009, Circulation. Heart failure.

[13]  J. Meléndez-Zajgla,et al.  Tissue Inhibitor of Metalloproteinases-4. The road less traveled , 2008, Molecular Cancer.

[14]  Leslie L. Clark,et al.  Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease , 2006, Circulation.

[15]  Xu-wen Liu,et al.  Novel functions of TIMPs in cell signaling , 2006, Cancer and Metastasis Reviews.

[16]  R. Khokha,et al.  Combination of Tumor Necrosis Factor-α Ablation and Matrix Metalloproteinase Inhibition Prevents Heart Failure After Pressure Overload in Tissue Inhibitor of Metalloproteinase-3 Knock-Out Mice , 2005, Circulation research.

[17]  F. Gao,et al.  Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. , 2005, American journal of physiology. Heart and circulatory physiology.

[18]  James A. Clark,et al.  Estrogen receptor-β mediates male-female differences in the development of pressure overload hypertrophy , 2005 .

[19]  Yan-hong Guo,et al.  Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell migration and induces cell apoptosis. , 2004, Life sciences.

[20]  M. Zile,et al.  Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. , 2003, American journal of physiology. Heart and circulatory physiology.

[21]  M. Zile,et al.  Myocardial Infarct Expansion and Matrix Metalloproteinase Inhibition , 2003, Circulation.

[22]  Arantxa González,et al.  Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.

[23]  F. Spinale Matrix metalloproteinases: regulation and dysregulation in the failing heart. , 2002, Circulation research.

[24]  N. Doll,et al.  Regression of Left Ventricular Hypertrophy After Surgical Therapy for Aortic Stenosis Is Associated With Changes in Extracellular Matrix Gene Expression , 2001, Circulation.

[25]  C. Overall,et al.  Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. , 2001, Cancer research.

[26]  F. Spinale,et al.  Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .

[27]  B. A. French,et al.  Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. , 1997, The Journal of clinical investigation.

[28]  J. Greene,et al.  Molecular Cloning and Characterization of Human Tissue Inhibitor of Metalloproteinase 4* , 1996, The Journal of Biological Chemistry.

[29]  J. Robbins,et al.  Transgenic analysis of the thyroid-responsive elements in the alpha-cardiac myosin heavy chain gene promoter. , 1993, The Journal of biological chemistry.

[30]  F. Spinale,et al.  Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. , 1991, Circulation research.

[31]  O. Hess,et al.  Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. , 1989, Circulation.

[32]  O. Hess,et al.  Time course of regression of left ventricular hypertrophy after aortic valve replacement. , 1988, Circulation.

[33]  M. Zile,et al.  Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. , 2012, The Journal of thoracic and cardiovascular surgery.

[34]  K. Brew,et al.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.

[35]  M. Zile,et al.  Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. , 2000, Journal of molecular and cellular cardiology.

[36]  V. Regitz-Zagrosek,et al.  Leading article , 1964 .